Combined treatment of sinapic acid and ellagic acid attenuates hyperglycemia in streptozotocin-induced diabetic rats

In the present study, we aimed to investigate the effect of individual and combined treatment of sinapic acid (SA) and ellagic acid (EA) in streptozotocin (STZ)-induced diabetic rats. Rats were divided into eight groups (n = 7): Normal Control, Diabetic Control, Diabetic + Sinapic Acid, Diabetic + Ellagic Acid, Diabetic + Sinapic Acid + Ellagic Acid, Sinapic Acid, Ellagic Acid and Sinapic Acid + Ellagic Acid. Diabetic groups were injected with a single dose of 50 mg/kg STZ intraperitoneally. Rats received 20 mg/kg/day SA and 50 mg/kg/day EA intragastrically for 28 days. The numerical density of immunopositive beta-cells and volume density of pancreatic islets were calculated. Additionally, glucose and insulin levels in serum, MDA, GSH, and CAT levels of pancreatic tissue were measured. While serum glucose levels increased, serum insulin levels decreased in STZ-induced diabetic rats. But these changes in glucose and insulin were restored by individual and combined treatments of SA and EA. Also, individual and combined treatments of SA and EA increased insulin expression of beta-cells in STZ-induced diabetic rats. Moreover, these compounds improved deteriorating oxidative stress parameters in STZ-induced diabetic rats. Our study indicates that SA and EA, especially their combined treatments, can be used as an antihyperglycemic agent in diabetes.

Automated summary

Our study demonstrates that individual and combined treatments of sinapic acid and ellagic acid can restore changes in glucose and insulin levels, increase insulin expression of beta-cells, and improve oxidative stress parameters in streptozotocin-induced diabetic rats.